R&D channel feed – Endpoints News

R&D channel feed

AstraZeneca celebrates a PhIII PARP success for Lynparza, putting pressure on Tesaro rival

9 years ago

Portola caps a problem-plagued year with an application for anticoagulant betrixaban

9 years ago

Dipexium shares eviscerated after lead antibiotic flops on a full slate of PhIII endpoints

9 years ago

Novartis promises a speedy CAR-T pitch, boasts about its slate of blockbusters-to-be

9 years ago

Backlash: Harvard experts fret over the fallout from FDA’s OK for Sarepta’s controversial Duchenne drug

9 years ago

Inovio shares slide after FDA hits it with a hold on lead PhIII HPV program

9 years ago

New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold

9 years ago

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal

9 years ago

Zeroing in on Merck rival, GSK steps up to the FDA with its top new vaccine prospect

9 years ago

Merck completes a clinical trial Odyssey, finally bagging an FDA OK for C diff antibody

9 years ago

Cerecor’s $1M Lilly deal put it in the right place at the right time today

9 years ago

Roche adjusts Avastin franchise defense plans as PhII successor fails a key study

9 years ago

Hot on the heels of its Bristol-Myers slapdown, Merck scores PhIII bladder cancer success with Keytruda

9 years ago

Alkermes plots course to the FDA after its depression drug scores success in last-stand PhIII

9 years ago

Gilead needs a big R&D hit. Here's why claims on NASH fall well short of that

9 years ago

Backed by neuro enthusiast Arch, upstart BlackThorn tackles some tough targets with $40M round

9 years ago

Rigel’s 2nd PhIII for fostamatinib scuttled by a single placebo response, shares crater

9 years ago

No surprise: AbbVie turns cold shoulder to a messy rheumatoid arthritis partnership with Ablynx

9 years ago

Eli Lilly wins a quick OK for new sarcoma drug olaratumab

9 years ago

Now that Sarepta has bolted out of the barn, the FDA wants to shut the door

9 years ago

Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug

9 years ago

Cancer powerhouse Roche elbows its way into a checkpoint showdown with Bristol-Myers, Merck

9 years ago

Oxford spinout Argonaut looks to hack cancer cells and program them to die

9 years ago

Merck bags a PhIII CMV victory in the wake of a flop at rival Chimerix

9 years ago

First page Previous page 314 315 316317318 319 320 Next page Last page